

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

John Biteau *et al.*

Serial No.: 10/567,725

Filed: January 30, 2006

For: OPTICAL ARTICLE COMPRISING A
MULTILAYER ANTI-REFLECTIVE
COATING AND METHOD FOR
PRODUCTION THEREOF

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: ESSR:104US

CERTIFICATE OF ELECTRONIC FILING

DATE OF FILING : August 7, 2006

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES DATED JULY 7, 2006**

MAIL STOP PCT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 23313-1450

Commissioner:

This paper is submitted in response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated July 7, 2006 (the "Notification"), for which the date for response is September 7, 2006.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Account L.L.P. No.: 50-1212/ESSR:104US.


A Response to the Notification begins on page 2 of this paper.

RESPONSE

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated July 7, 2006 (a copy of which is enclosed), Applicants respectfully point out that there are no nucleotide or amino acid sequence disclosures contained in this application. Rather, this application contains various chemical formulas, wherein the letters represent atoms or groups thereof. Therefore, no Sequence Listing is required for this application.

Should the Examiner have any questions or comments regarding this matter, a telephone call to the undersigned Applicants' representative is earnestly solicited.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
512.536.3035 (voice)
512.536.4598 (fax)

Date: August 7, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 PO Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/567,725	John Biteau	ESSR:104US
FULBRIGHT & JAWORSKI, LLP <small>INT'L DOCKETING</small> Docketed <input checked="" type="checkbox"/> Not Req'd <input type="checkbox"/> Confirmation <input type="checkbox"/> <small>Initials 1st [Signature] Initials 2nd [Signature]</small>		INTERNATIONAL APPLICATION NO. PCT/FR04/50364
32425 FULBRIGHT & JAWORSKI L.L.P. 600 CONGRESS AVE. SUITE 2400 AUSTIN, TX 78701	JUL 18 2006 Attorney <u>MBw</u> Docket No. <u>ESSR:104US</u> Action Req'd <u>Missing Part 97/06</u> Date Due <u>Final 27/07</u>	I.A. FILING DATE 07/28/2004
Date Mailed: 07/07/2006		PRIORITY DATE 07/29/2003

CONFIRMATION NO. 7693
 371 FORMALITIES LETTER



OC000000019514702

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application**. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/567,725	PCT/FR04/50364	ESSR:104US

FORM PCT/DO/EO/922 (371 Formalities Notice)